An active phase I clinical trial (NCT02285816) is assessing MG1-MAGEA3 with and without Ad-MAGEA3 in patients with incurable, advanced, or metastatic MAGE-A3-expressing solid tumors, including NSCLC (adenocarcinoma and squamous cell carcinoma), although results have not yet been reported [51]. Here, MAGEA3 is linked to squamous cell carcinoma.